57
Participants
Start Date
May 1, 2024
Primary Completion Date
April 1, 2027
Study Completion Date
October 15, 2027
M1774
• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
Fulvestrant injection
Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
Institut Paoli Calmettes, Marseille
National Cancer Institute, France
OTHER_GOV
Merck KGaA, Darmstadt, Germany
INDUSTRY
Institut Paoli-Calmettes
OTHER